Literature DB >> 15607363

Heterogeneous somatic hypermutation status confounds the cell of origin in hairy cell leukemia.

Mia Thorsélius1, Sarah H Walsh, Ulf Thunberg, Hans Hagberg, Christer Sundström, Richard Rosenquist.   

Abstract

Hairy cell leukemia (HCL) is thought to arise from a post-germinal center (GC) B-cell, however the exact normal counterpart remains unclear. We performed VH gene analysis of 32 HCL cases, revealing somatically mutated VH genes (<98% homology) in 27 cases and unmutated VH genes in five cases, four of which displayed germline VH genes. Intraclonal heterogeneity was evident in the majority of eight mutated HCLs investigated, although at a lower level compared to GC-derived lymphomas. A novel finding of preferential VH3-30 gene usage was detected (19% of HCLs). Our data confounds the postulated post-GC origin in HCL considering (1) the finding of unmutated HCLs, generally correlating with a pre-GC origin, and (2) the presence of intraclonal variation in mutated HCLs. The latter suggests that the transformed B-cell was frozen when it still had an active mutation process, implying a closer relation to the GC than previously assumed. Furthermore, restricted VH3-30 usage indicates that antigen selection could be a promoting factor in HCL development.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15607363     DOI: 10.1016/j.leukres.2004.05.016

Source DB:  PubMed          Journal:  Leuk Res        ISSN: 0145-2126            Impact factor:   3.156


  10 in total

Review 1.  Hairy cell leukemia.

Authors:  Ronan Swords; Francis Giles
Journal:  Med Oncol       Date:  2007       Impact factor: 3.064

Review 2.  Hairy cell leukemia: update and current therapeutic approach.

Authors:  Latif Salam; Omar Abdel-Wahab
Journal:  Curr Opin Hematol       Date:  2015-07       Impact factor: 3.284

3.  Evidence of canonical somatic hypermutation in hairy cell leukemia.

Authors:  Evgeny Arons; Laura Roth; Jeffrey Sapolsky; Tara Suntum; Maryalice Stetler-Stevenson; Robert J Kreitman
Journal:  Blood       Date:  2011-03-02       Impact factor: 22.113

4.  Long-term durable remission by cladribine followed by rituximab in patients with hairy cell leukaemia: update of a phase II trial.

Authors:  Dai Chihara; Hagop Kantarjian; Susan O'Brien; Jeffrey Jorgensen; Sherry Pierce; Stefan Faderl; Alessandra Ferrajoli; Rebecca Poku; Preetesh Jain; Phillip Thompson; Mark Brandt; Rajyalakshmi Luthra; Jan Burger; Michael Keating; Farhad Ravandi
Journal:  Br J Haematol       Date:  2016-06-15       Impact factor: 6.998

Review 5.  Hairy cell leukemia.

Authors:  Claire Dearden; Monica Else
Journal:  Curr Oncol Rep       Date:  2006-09       Impact factor: 5.075

Review 6.  Immunoglobulin gene analysis of mature B-cell malignancies: reconsideration of cellular origin and potential antigen involvement in pathogenesis.

Authors:  Sarah H Walsh; Richard Rosenquist
Journal:  Med Oncol       Date:  2005       Impact factor: 3.064

7.  Class II human leucocyte antigen DRB1*11 in hairy cell leukaemia patients with and without haemolytic uraemic syndrome.

Authors:  Evgeny Arons; Sharon Adams; David J Venzon; Ira Pastan; Robert J Kreitman
Journal:  Br J Haematol       Date:  2014-06-13       Impact factor: 6.998

8.  Hematopoietic stem cell origin of BRAFV600E mutations in hairy cell leukemia.

Authors:  Stephen S Chung; Eunhee Kim; Jae H Park; Christopher Y Park; Omar Abdel-Wahab; Young Rock Chung; Piro Lito; Julie Teruya-Feldstein; Wenhuo Hu; Wendy Beguelin; Sebastien Monette; Cihangir Duy; Raajit Rampal; Leon Telis; Minal Patel; Min Kyung Kim; Kety Huberman; Nancy Bouvier; Michael F Berger; Ari M Melnick; Neal Rosen; Martin S Tallman
Journal:  Sci Transl Med       Date:  2014-05-28       Impact factor: 17.956

9.  VH4-34+ hairy cell leukemia, a new variant with poor prognosis despite standard therapy.

Authors:  Evgeny Arons; Tara Suntum; Maryalice Stetler-Stevenson; Robert J Kreitman
Journal:  Blood       Date:  2009-09-10       Impact factor: 22.113

10.  Clinical observations on chemotherapy curable malignancies: unique genetic events, frozen development and enduring apoptotic potential.

Authors:  Philip Savage
Journal:  BMC Cancer       Date:  2015-01-21       Impact factor: 4.430

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.